The White House
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.
The Conference Board's principal economic policy analyst PJ Tabit says that while the plan is helpful, it is not a comprehensive framework for how to regulate AI.